Dr. Stephan Grupp, MD
Claim this profileChildren's Hospital of Philadelphia
Studies Leukemia
Studies Lymphoma
8 reported clinical trials
9 drugs studied
Area of expertise
1Leukemia
CD22 positive
HLA negative
CD3 positive
2Lymphoma
CD22 positive
Affiliated Hospitals
Clinical Trials Stephan Grupp, MD is currently running
Steroid Tapering
for Pediatric Graft-versus-Host Disease
The standard treatment for acute graft-vs-host disease (GVHD) is to suppress the activity of the donor immune cells using steroid medications such as prednisone. Although most GVHD, especially in children, responds well to treatment, sometimes (around 1/3 of the time) there is either no response to steroids or the response does not last. In those cases, the GVHD can become dangerous and even life-threatening. Unfortunately, doctors cannot predict who will have a good response to treatment based on symptom severity or initial response to steroids. As a result, nearly all children who develop GVHD are treated with long courses of high dose steroids even though that means many patients receive more treatment than they probably need. Steroid treatment can cause short-term complications like infections, high blood sugar, high blood pressure, muscle weakness, depression, anxiety, and problems sleeping and long-term complications like bone damage, cataracts in the eyes, and decreased growth. The risk of these complications increases with higher doses of steroids and longer treatment. It is important to find ways to decrease the steroid treatment in patients who do not need long courses. The doctors conducting this research have developed a blood test (GVHD biomarkers) that predicts whether a patient will respond well to steroids. The study team found that children who have low GVHD biomarkers at the start of treatment and for the first two weeks of treatment have a very high response rate to steroids. In this study, the study team will monitor GVHD symptoms and biomarkers during treatment and taper steroids quickly in patients who have GVHD that is expected to respond very well to treatment. The study team will assess how many patients respond well to lower steroid dosing and what steroid complications develop. The study team will also use surveys to obtain the patient's own assessment of their quality of life (down to age 5 years).
Recruiting1 award Phase 2
CART22 Therapy
for B-Cell Leukemia
This is a pilot study to determine the feasibility and safety of a single dose of autologous T cells expressing CD22 chimeric antigen receptors expressing tandem TCR-ζ and 4-1BB signaling domains (CART22/CART22-65s cells) in pediatric and young adult subjects with relapsed or refractory B cell acute lymphoblastic leukemia.
Recruiting1 award Phase 1
More about Stephan Grupp, MD
Clinical Trial Related2 years of experience running clinical trials · Led 8 trials as a Principal Investigator · 5 Active Clinical TrialsTreatments Stephan Grupp, MD has experience with
- CART22 Cells
- Prednisone
- Tisagenlecleucel
- CAR-T
- CTL019
- CliniMACs
Breakdown of trials Stephan Grupp, MD has run
Leukemia
Lymphoma
T-Lymphoblastic Leukemia/Lymphoma
B-Cell Lymphoma
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Stephan Grupp, MD specialize in?
Stephan Grupp, MD focuses on Leukemia and Lymphoma. In particular, much of their work with Leukemia has involved CD22 positive patients, or patients who are HLA negative.
Is Stephan Grupp, MD currently recruiting for clinical trials?
Yes, Stephan Grupp, MD is currently recruiting for 5 clinical trials in Philadelphia Pennsylvania. If you're interested in participating, you should apply.
Are there any treatments that Stephan Grupp, MD has studied deeply?
Yes, Stephan Grupp, MD has studied treatments such as CART22 cells, Prednisone, Tisagenlecleucel.
What is the best way to schedule an appointment with Stephan Grupp, MD?
Apply for one of the trials that Stephan Grupp, MD is conducting.
What is the office address of Stephan Grupp, MD?
The office of Stephan Grupp, MD is located at: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania 19104 United States. This is the address for their practice at the Children's Hospital of Philadelphia.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.